Dengue Testing Market Size, Share, Trends, Growth Outlook

Dengue Testing Market is estimated to increase at a Compounded Annual Growth Rate of 4.9% CAGR over the forecast period from 2024 to 2030

The Dengue Testing Market study analyzes and forecasts the market size across 6 regions and 24 countries for diverse segments- By Product (ELISA-based Tests, RT-PCR based Tests, Dengue IgG/IgM Rapid Test, Others), By End-User (Hospitals, Diagnostic Centers, Others).

An Introduction to Dengue Testing Market in 2024

In 2024, the market for dengue testing addresses the global public health challenge of dengue fever, offering diagnostic assays, serological tests, and molecular assays for detecting dengue virus infection, differentiating dengue virus serotypes, and monitoring disease progression in endemic regions and outbreak settings. Dengue fever is a mosquito-borne viral illness caused by dengue virus serotypes 1-4, transmitted primarily by Aedes mosquitoes, and is endemic in tropical and subtropical regions worldwide. Dengue testing plays a crucial role in early diagnosis, patient management, and disease surveillance efforts, allowing healthcare providers to promptly identify and isolate infected individuals, implement vector control measures, and prevent further transmission of the virus. Diagnostic tests for dengue include nucleic acid amplification tests (NAATs), antigen detection assays, and antibody-based tests such as enzyme-linked immunosorbent assays (ELISAs) and rapid diagnostic tests (RDTs), each offering specific advantages in terms of sensitivity, specificity, and turnaround time for dengue diagnosis and serological profiling. With a focus on rapid diagnosis, point-of-care testing, and laboratory capacity building, dengue testing technologies support timely clinical decision-making, public health surveillance, and outbreak response efforts in regions affected by dengue fever. Moreover, with advancements in diagnostic test performance, multiplex testing platforms, and surveillance strategies, the dengue testing market contributes to improved disease detection, epidemiological understanding, and control measures for combating dengue fever and reducing its global burden on healthcare systems and communities.

Market Trend: Increasing Demand for Rapid Diagnostic Tests

A significant trend in the Dengue Testing market is the increasing demand for rapid diagnostic tests (RDTs). With the rising incidence of dengue fever globally and the growing recognition of its public health significance, there's a heightened need for timely and accurate diagnostic solutions. Rapid diagnostic tests offer several advantages over traditional laboratory-based methods, including shorter turnaround times, ease of use, and suitability for point-of-care testing in resource-limited settings. As healthcare systems prioritize early detection and management of dengue infections to prevent complications and reduce transmission rates, there's a growing adoption of RDTs by healthcare providers, clinics, and public health agencies. This trend reflects the shift towards decentralized testing approaches and the increasing importance of rapid diagnostic tools in combating dengue outbreaks and improving patient care.

Market Driver: Growing Global Burden of Dengue Fever

An important driver fueling the Dengue Testing market is the growing global burden of dengue fever. Dengue is a mosquito-borne viral infection caused by the dengue virus, transmitted primarily by Aedes mosquitoes. The disease is endemic in tropical and subtropical regions, with millions of cases reported annually worldwide. Dengue fever can manifest as a mild febrile illness or progress to severe forms, including dengue hemorrhagic fever (DHF) and dengue shock syndrome (DSS), which can be life-threatening without prompt diagnosis and treatment. The increasing incidence of dengue outbreaks, urbanization, climate change, and globalization have contributed to the spread of the disease to new geographic areas and populations, amplifying the need for effective diagnostic strategies. As healthcare systems grapple with the challenges posed by dengue epidemics and strive to enhance surveillance and control efforts, there's a growing demand for reliable diagnostic tests to facilitate early case detection, outbreak management, and disease monitoring.

Market Opportunity: Development of Multiplex and Point-of-Care Testing Solutions

A significant opportunity within the Dengue Testing market lies in the development of multiplex and point-of-care testing solutions. While rapid diagnostic tests have improved access to dengue testing in endemic regions, there's potential for innovation to further enhance test performance, accuracy, and versatility. Opportunities exist for the development of multiplex assays capable of detecting multiple dengue virus serotypes simultaneously, enabling differentiation between primary and secondary infections and providing valuable epidemiological information. Additionally, there's a growing demand for point-of-care testing solutions that offer rapid and accurate dengue diagnosis at the patient's bedside or in community settings, facilitating timely clinical decision-making and outbreak response. By investing in research and development initiatives focused on multiplex and point-of-care testing technologies, stakeholders in the Dengue Testing market can address current diagnostic challenges, improve disease surveillance, and contribute to effective dengue prevention and control strategies.

Dengue Testing Market Share Analysis: Dengue IgG/IgM Rapid Test

Among the various products in the Dengue Testing market, the Dengue IgG/IgM Rapid Test segment is experiencing the fastest growth. Several factors contribute to the rapid expansion of the Dengue IgG/IgM Rapid Test segment in the Dengue Testing market. Firstly, the Dengue IgG/IgM Rapid Test offers several advantages over traditional testing methods, including rapid results (typically within 15-20 minutes), ease of use, and no requirement for specialized laboratory equipment or trained personnel. These characteristics make rapid tests ideal for point-of-care testing in resource-limited settings, where timely diagnosis and patient management are critical for controlling dengue outbreaks and reducing disease burden. Secondly, the Dengue IgG/IgM Rapid Test demonstrates high sensitivity and specificity in detecting dengue virus antibodies, enabling accurate diagnosis of dengue infection and differentiation between primary and secondary dengue infections. This distinction is crucial for guiding clinical management decisions, such as appropriate patient triage, monitoring disease progression, and implementing targeted interventions to prevent complications. Additionally, the Dengue IgG/IgM Rapid Test facilitates early detection of dengue infection, allowing healthcare providers to initiate timely supportive care and interventions to reduce morbidity and mortality associated with severe dengue, including dengue hemorrhagic fever (DHF) and dengue shock syndrome (DSS). Moreover, the increasing prevalence of dengue fever globally, driven by factors such as urbanization, climate change, and globalization, fuels the demand for rapid and accurate diagnostic tests for dengue virus infection. As countries strive to strengthen their dengue surveillance and control programs, rapid tests play a vital role in early case detection, outbreak response, and epidemiological monitoring of dengue transmission dynamics. Furthermore, the availability of Dengue IgG/IgM Rapid Tests through various end-users, including hospitals, diagnostic centers, and others, enhances accessibility and coverage of dengue testing services, particularly in underserved communities and regions endemic for dengue fever. Consequently, the Dengue IgG/IgM Rapid Test emerges as the Dengue Testing market, offering significant opportunities for manufacturers, healthcare providers, and stakeholders involved in dengue surveillance, prevention, and control efforts.

Dengue Testing Competitive Analysis

The market research study provides in-depth insights into leading companies including the SWOT analyses, product profile, financial details, and recent developments acrossAbbott Laboratories, Abnova Corp, Certest Biotec SL, DiaSorin S.p.A., F. Hoffmann-La Roche Ltd, Immundiagnostik AG, InBios International Inc, NovaTec Immundiagnostica GmbH, OriGene Technologies Inc, PerkinElmer Inc, Quest Diagnostics Inc, Thermo Fisher Scientific Inc

Dengue Testing Market Segmentation

By Product
ELISA-based Tests
RT-PCR based Tests
Dengue IgG/IgM Rapid Test
Others
By End-User
Hospitals
Diagnostic Centers
Others
Geographical Analysis
North America (United States, Canada, Mexico)
Europe (Germany, France, United Kingdom, Spain, Italy, Rest of Europe)
Asia Pacific (China, India, Japan, South Korea, Rest of Asia Pacific)
South America (Brazil, Argentina, Rest of South America)
Middle East and Africa (Saudi Arabia, UAE, Rest of Middle East, South Africa, Egypt, Rest of Africa)

Dengue Testing Market Companies

Abbott Laboratories
Abnova Corp
Certest Biotec SL
DiaSorin S.p.A.
F. Hoffmann-La Roche Ltd
Immundiagnostik AG
InBios International Inc
NovaTec Immundiagnostica GmbH
OriGene Technologies Inc
PerkinElmer Inc
Quest Diagnostics Inc
Thermo Fisher Scientific Inc

Reasons to Buy the Dengue Testing Market Study

• Deepen your industry insights and navigate uncertainties for strategy formulation, CAPEX, and Operational decisions
• Gain access to detailed insights on the Dengue Testing Market, encompassing current market size, growth trends, and forecasts till 2030.
• Access detailed competitor analysis, enabling competitive advantage through a thorough understanding of market players, strategies, and potential differentiation opportunities
• Stay ahead of the curve with insights on technological advancements, innovations, and upcoming trends
• Identify lucrative investment avenues and expansion opportunities within the Dengue Testing Market industry, guided by robust, data-backed analysis.
• Understand regional and global markets through country-wise analysis, regional market potential, regulatory nuances, and dynamics
• Execute strategies with confidence and speed through information, analytics, and insights on the industry value chain
• Corporate leaders, strategists, financial experts, shareholders, asset managers, and governmental representatives can make long-term planning scenarios and build an integrated and timely understanding of market dynamics
• Benefit from tailored solutions and expert consultation based on report insights, providing personalized strategies aligned with specific business needs.

TABLE OF CONTENTS

1 Introduction to 2024 Dengue Testing Market
1.1 Market Overview
1.2 Quick Facts
1.3 Scope/Objective of the Study
1.4 Market Definition
1.5 Countries and Regions Covered
1.6 Units, Currency, and Conversions
1.7 Industry Value Chain

2 Research Methodology
2.1 Market Size Estimation
2.2 Sources and Research Methodology
2.3 Data Triangulation
2.4 Assumptions and Limitations

3 Executive Summary
3.1 Global Dengue Testing Market Size Outlook, $ Million, 2021 to 2030
3.2 Dengue Testing Market Outlook by Type, $ Million, 2021 to 2030
3.3 Dengue Testing Market Outlook by Product, $ Million, 2021 to 2030
3.4 Dengue Testing Market Outlook by Application, $ Million, 2021 to 2030
3.5 Dengue Testing Market Outlook by Key Countries, $ Million, 2021 to 2030

4 Market Dynamics
4.1 Key Driving Forces of Dengue Testing Industry
4.2 Key Market Trends in Dengue Testing Industry
4.3 Potential Opportunities in Dengue Testing Industry
4.4 Key Challenges in Dengue Testing Industry

5 Market Factor Analysis
5.1 Value Chain Analysis
5.2 Competitive Landscape
5.2.1 Global Dengue Testing Market Share by Company (%), 2023
5.2.2 Product Offerings by Company
5.3 Porter’s Five Forces Analysis
5.4 Pricing Analysis and Outlook

6 Growth Outlook Across Scenarios
6.1 Growth Analysis-Case Scenario Definitions
6.2 Low Growth Scenario Forecasts
6.3 Reference Growth Scenario Forecasts
6.4 High Growth Scenario Forecasts

7 Global Dengue Testing Market Outlook by Segments
7.1 Dengue Testing Market Outlook by Segments, $ Million, 2021- 2030
By Product
ELISA-based Tests
RT-PCR based Tests
Dengue IgG/IgM Rapid Test
Others
By End-User
Hospitals
Diagnostic Centers
Others

8 North America Dengue Testing Market Analysis and Outlook To 2030
8.1 Introduction to North America Dengue Testing Markets in 2024
8.2 North America Dengue Testing Market Size Outlook by Country, 2021-2030
8.2.1 United States
8.2.2 Canada
8.2.3 Mexico
8.3 North America Dengue Testing Market size Outlook by Segments, 2021-2030
By Product
ELISA-based Tests
RT-PCR based Tests
Dengue IgG/IgM Rapid Test
Others
By End-User
Hospitals
Diagnostic Centers
Others

9 Europe Dengue Testing Market Analysis and Outlook To 2030
9.1 Introduction to Europe Dengue Testing Markets in 2024
9.2 Europe Dengue Testing Market Size Outlook by Country, 2021-2030
9.2.1 Germany
9.2.2 France
9.2.3 Spain
9.2.4 United Kingdom
9.2.4 Italy
9.2.5 Russia
9.2.6 Norway
9.2.7 Rest of Europe
9.3 Europe Dengue Testing Market Size Outlook by Segments, 2021-2030
By Product
ELISA-based Tests
RT-PCR based Tests
Dengue IgG/IgM Rapid Test
Others
By End-User
Hospitals
Diagnostic Centers
Others

10 Asia Pacific Dengue Testing Market Analysis and Outlook To 2030
10.1 Introduction to Asia Pacific Dengue Testing Markets in 2024
10.2 Asia Pacific Dengue Testing Market Size Outlook by Country, 2021-2030
10.2.1 China
10.2.2 India
10.2.3 Japan
10.2.4 South Korea
10.2.5 Indonesia
10.2.6 Malaysia
10.2.7 Australia
10.2.8 Rest of Asia Pacific
10.3 Asia Pacific Dengue Testing Market size Outlook by Segments, 2021-2030
By Product
ELISA-based Tests
RT-PCR based Tests
Dengue IgG/IgM Rapid Test
Others
By End-User
Hospitals
Diagnostic Centers
Others

11 South America Dengue Testing Market Analysis and Outlook To 2030
11.1 Introduction to South America Dengue Testing Markets in 2024
11.2 South America Dengue Testing Market Size Outlook by Country, 2021-2030
11.2.1 Brazil
11.2.2 Argentina
11.2.3 Rest of South America
11.3 South America Dengue Testing Market size Outlook by Segments, 2021-2030
By Product
ELISA-based Tests
RT-PCR based Tests
Dengue IgG/IgM Rapid Test
Others
By End-User
Hospitals
Diagnostic Centers
Others
12 Middle East and Africa Dengue Testing Market Analysis and Outlook To 2030
12.1 Introduction to Middle East and Africa Dengue Testing Markets in 2024
12.2 Middle East and Africa Dengue Testing Market Size Outlook by Country, 2021-2030
12.2.1 Saudi Arabia
12.2.2 UAE
12.2.3 Oman
12.2.4 Rest of Middle East
12.2.5 Egypt
12.2.6 Nigeria
12.2.7 South Africa
12.2.8 Rest of Africa
12.3 Middle East and Africa Dengue Testing Market size Outlook by Segments, 2021-2030
By Product
ELISA-based Tests
RT-PCR based Tests
Dengue IgG/IgM Rapid Test
Others
By End-User
Hospitals
Diagnostic Centers
Others

13 Company Profiles
13.1 Company Snapshot
13.2 SWOT Profiles
13.3 Products and Services
13.4 Recent Developments
13.5 Financial Profile
List of Companies
Abbott Laboratories
Abnova Corp
Certest Biotec SL
DiaSorin S.p.A.
F. Hoffmann-La Roche Ltd
Immundiagnostik AG
InBios International Inc
NovaTec Immundiagnostica GmbH
OriGene Technologies Inc
PerkinElmer Inc
Quest Diagnostics Inc
Thermo Fisher Scientific Inc

14 Appendix
14.1 Customization Offerings
14.2 Subscription Services
14.3 Related Reports
14.4 Publisher Expertise

By Product
ELISA-based Tests
RT-PCR based Tests
Dengue IgG/IgM Rapid Test
Others
By End-User
Hospitals
Diagnostic Centers
Others
Countries Analyzed
North America (United States, Canada, Mexico)
Europe (Germany, France, United Kingdom, Spain, Italy, Rest of Europe)
Asia Pacific (China, India, Japan, South Korea, Rest of Asia Pacific)
South America (Brazil, Argentina, Rest of South America)
Middle East and Africa (Saudi Arabia, UAE, Rest of Middle East, South Africa, Egypt, Rest of Africa)